ClinicalTrials.gg

Eczema clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 506 studies for Eczema across more than 10 countries. 90 are recruiting or about to start. 137 of them are mainly about Eczema (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16.

ClinicalTrials.gov finds 1,770 studies for Eczema. How that becomes 503 here

This page counts the studies the registry files under Eczema, and those it files under no condition that list Eczemathemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 1,770Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −79List Eczema as a condition, but the registry did not file them under itMost often written as “Atopic Eczema” (23), “Atopic Dermatitis Eczema” (12), and “Eczema, Atopic” (9). The registry filed 1 of them under no condition at all, and the others under other conditions only, most often Dermatitis, Atopic (59) and Kaposi Varicelliform Eruption (6).
  3. −1,188Match it another way40 name it in the title, 23 in a keyword, and 1,125 by a synonym or other text the search reads.
  4. 503The count on this page48 of them list Eczema in their own words; the registry filed them under no condition.

Status

Completed
295
Recruiting
66
Status unknown
36
Terminated
36
Active, not recruiting
28
Withdrawn
19

Phase

Phase 2
130
Phase 3
100
Phase 1
38
Phase 4
33
Early Phase 1
2

Where

United States
251
Canada
110
Germany
81
Poland
72
United Kingdom
48
Spain
47

Who develops what

Add Eczema to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 23 programs from 17 companies, 3 with this as their studies’ main aim; 5 with a live phase 3 study; 7 primary completions in the next 12 months. Compare Pfizer, Arcutis Biotherapeutics and Novartis here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
dupilumabRecent, limited
Evidence
  • NCT07783425 · Pfizer · Phase 3 · live · comparator · “Dupilumab” · registered Aug 2026
  • NCT04345367 · Pfizer · Phase 3 · comparator · “Dupilumab 300 mg” · registered Mar 2020
  • NCT03720470 · Pfizer · Phase 3 · comparator · “Dupilumab” · registered Oct 2018
Sanofi56% of its industry studiesUS: Regeneron Pharmaceuticals (FDA 2017)EU: Sanofi (EMA 2017)11 study
Topical CorticosteroidRecent, limitedPhase 4 trial recorded
Evidence
  • NCT05559359 · Eli Lilly and Company · Phase 3 · live · background · “Topical Corticosteroid (TCS)” · registered Sep 2022
  • NCT04760314 · Eli Lilly and Company · Phase 3 · background · “Topical Corticosteroid” · registered Feb 2021
  • NCT03952559 · Eli Lilly and Company · Phase 3 · background · “Topical corticosteroid” · registered May 2019
  • NCT03733301 · Eli Lilly and Company · Phase 3 · background · “Topical corticosteroid” · registered Oct 2018
  • NCT03428100 · Eli Lilly and Company · Phase 3 · background · “Topical corticosteroid” · registered Feb 2018
AbbVie67% of its industry studies11 study
AlitretinoinRecent, limited
Evidence
  • NCT05259722 · LEO Pharma · Phase 3 · comparator · “Toctino” · registered Feb 2022
Basilea Pharmaceutica50% of its industry studiesUS: Advanz Pharma (FDA 1999)11 study

1 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
GX-03☆ Track1 live phase-3 study: NCT07355075Turn Therapeutics
abrocitinibApproved: US 2022 · EU 2021☆ Track3 live phase-3 studies: NCT06807268, NCT06807281, NCT07823595Pfizer

The 2 in phase 3 with the nearest primary completion, of 23 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (7)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 20 Jan 2027 est.GX-03 · Turn Therapeutics · Phase 3 main aimNCT07355075 A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema) — primary endpoint: vIGA-AD Success at Week 4 · 190 enrolled
  • 28 Feb 2027 est.BFB759 · Bluefin Biomedicine, Inc. · Phase 2 registry mapping onlyNCT07105488 A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis — primary endpoint: Efficacy of BFB759 in AD · 225 enrolled
  • 2 May 2027 est.abrocitinib · Pfizer · Phase 3 main aimNCT06807268 A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema — primary endpoint: Response based on achieving Validated Investigator's Global Assessment (vIGA) score of clear (0) or almost clear (1) (on a 5-point scale) and a reduction from baseline of ≥2 points at Week 12 · 151 enrolled

4 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Eczema studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 3 open · JAK inhibitors 2 open · Calcineurin inhibitors 9 · Corticosteroids 7

Coming up

32studies finish main data collection within a year6 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 66 Eczema studies recruiting now, 31 (47%) set no upper age limit and 27 (41%) stop at 75 or younger. 35 (53%) take children under 18. 7 (11%) are for women only and 0 (0%) for men only; 22 (33%) take healthy volunteers.

Recruiting studies that take each age, of 66
AgeWomenMen
1021 (32%)20 (30%)
1851 (77%)45 (68%)
3052 (79%)46 (70%)
4053 (80%)46 (70%)
5051 (77%)47 (71%)
6546 (70%)44 (67%)
7539 (59%)37 (56%)
8537 (56%)35 (53%)

Across all 506 studies, recruiting or not: 48% stop at 75 or younger and 38% at 65; 46% take children; 3% are for women only and <1% for men only; 24% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Eczema studies take

Of 71 phase 3 interventional studies under Eczema, half reached primary completion within 18 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 116 mo5–20 · 16 studies——
Phase 214 mo10–26 · 70 studies13 mo9–16 · 54 studies—
Phase 318 mo13–28 · 71 studies18 mo13–26 · 66 studies—
Interventional, no phase12 mo4–23 · 79 studies4 mo2–11 · 33 studies17 mo10–44 · 46 studies
Observational70 mo29–… · 47 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 506. Browse all 506 → or search them.